| FibroGen is a biopharmaceutical company engaged in discovering, developing and commercializing a pipeline of therapeutics. Co. applies its capability in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, Co.'s primary product, is an inhibitor of HIF prolyl hydroxylase that acts by stimulating the body's natural pathway of erythropoiesis, or red blood cell production. Pamrevlumab is Co.'s human monoclonal antibody that inhibits the activity of CTGF, a central mediator and key common element in the progression of fibrotic and fibro-proliferative diseases. The FGEN YTD return is shown above.
The YTD Return on the FGEN YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether FGEN YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the FGEN YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.